Zai Lab Limited
HKSE: 9688.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ying Du
- Employees
- 1,869
- Headquarters
- Shanghai, China
- IPO year
- 2020
- Market cap
- HK$17.0B
- Website
- https://www.zailaboratory.com
Loading 9688…
Loading profile data…Frequently asked questions about 9688
What does Zai Lab Limited (9688.HK) do?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
Where does 9688.HK trade?
Zai Lab Limited (9688.HK) trades on the Hong Kong Stock Exchange.
What sector is 9688.HK in?
Zai Lab Limited (9688.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zai Lab Limited?
Ying Du is the chief executive officer of Zai Lab Limited (9688.HK).
Where is Zai Lab Limited headquartered?
Zai Lab Limited is headquartered in China.
Does 9688.HK pay a dividend?
Zai Lab Limited (9688.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 9688.HK go public?
Zai Lab Limited (9688.HK) completed its initial public offering in 2020.